Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Endocyte Reports DSMB Recommendations Following Interim Futility Analysis

RELATED NEWS
Trade ECYT now with 
10/11/2013 7:56 AM ET

Endocyte, Inc. (ECYT: Quote) unveiled the outcomes of the planned independent Data Safety Monitoring Board or DSMB review of the interim futility analysis for the Phase 2b TARGET study with investigational candidate vintafolide. The DSMB urged the continuation of the vintafolide combination therapy and docetaxel monotherapy arms of the trial.

In addition, the DSMB recommended investigators and patients be advised that vintafolide monotherapy is not likely to be declared superior to docetaxel in progression-free survival or PFS at the end of the study, and patients currently on vintafolide monotherapy may continue treatment based on guidance from their investigator. The TARGET trial's top-line results are expected in early 2014.

TARGET is being conducted in non-small cell lung cancer patients with all lesions expressing the folate receptor, as determined by the investigational companion imaging agent etarfolatide. This randomized trial is fully enrolled and comprised two investigational arms, vintafolide monotherapy and vintafolide in combination with docetaxel, each of which is compared to a standard of care control arm, docetaxel monotherapy.

The primary endpoint of the trial is PFS, powered to show a 50 percent improvement in PFS compared to the control arm, while secondary endpoints include the comparison of overall response rate, overall survival and safety.

Register
To receive FREE breaking news email alerts for Endocyte, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After reporting a bigger than expected increase in new orders for U.S. manufactured durable goods in the previous month, the Commerce Department released a report on Thursday that once again showed stronger than expected durable goods orders growth in the month of March. The report said durable goods orders surged up by 2.6 percent in March after jumping by a revised 2.1 percent in February. First-time claims for U.S. unemployment benefits rose by more than expected in the week ended April 19th, according to a report released by the Labor Department on Thursday, with initial jobless claims climbing further off their recent lows. The report said initial jobless claims rose to 329,000, an increase of 24,000 from the previous week's revised figure of 305,000. After giving back some ground in the previous session, stocks are likely to move back to the upside in early trading on Thursday. The major index futures are currently pointing to a higher open for the markets, with the Dow futures up by 40 points.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.